The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?

Archive ouverte

Saint-Laurent, Céline | Mazeyrie, Laurène | Tajan, Mylène | Paccoud, Romain | Castan-Laurell, Isabelle | Valet, Philippe | Edouard, Thomas | Pradère, Jean-Philippe | Dray, Cédric | Yart, Armelle

Edité par CCSD ; MDPI -

International audience. The SH2 containing protein tyrosine phosphatase 2(SHP2) plays essential roles in fundamental signaling pathways, conferring on it versatile physiological functions during development and in homeostasis maintenance, and leading to major pathological outcomes when dysregulated. Many studies have documented that SHP2 modulation disrupted glucose homeostasis, pointing out a relationship between its dysfunction and insulin resistance, and the therapeutic potential of its targeting. While studies from cellular or tissue-specific models concluded on both pros-and-cons effects of SHP2 on insulin resistance, recent data from integrated systems argued for an insulin resistance promoting role for SHP2, and therefore a therapeutic benefit of its inhibition. In this review, we will summarize the general knowledge of SHP2’s molecular, cellular, and physiological functions, explaining the pathophysiological impact of its dysfunctions, then discuss its protective or promoting roles in insulin resistance as well as the potency and limitations of its pharmacological modulation.

Suggestions

Du même auteur

SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations

Archive ouverte | Paccoud, Romain | CCSD

International audience. Hyperactive SHP2 promotes inflammation-driven insulin resistance by skewing macrophage balance in metabolic tissues and may be a target in T2D.

Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor

Archive ouverte | Personnaz, Jean | CCSD

International audience. Dysregulations of lipid metabolism in the liver may trigger steatosis progression, leading to potentially severe clinical consequences such as nonalcoholic fatty liver diseases (NAFLDs). Mole...

Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature

Archive ouverte | Serra-Nédélec, Audrey de Rocca | CCSD

Noonan syndrome (NS), a genetic disease caused in half of cases by activating mutations of the tyrosine phosphatase SHP2 (PTPN11), is characterized by congenital cardiopathies, facial dysmorphic features, and short stature. How mu...

Chargement des enrichissements...